Clarivate (CLVT) Goldman Sachs Communacopia + Technology Conference 2024 summary
Event summary combining transcript, slides, and related documents.
Goldman Sachs Communacopia + Technology Conference 2024 summary
20 Jan, 2026Organic growth targets and business segment performance
Targeting 4-6% organic revenue growth by 2026, with current progress in A&G and IP segments and ongoing investments to accelerate growth.
A&G segment subscription growth has exceeded 3% due to platform enhancements and AI-driven features like Researcher Assistant.
IP segment is recovering from market softness, with patent renewal volumes improving and new software solutions gaining traction.
Life sciences segment is being repositioned with a focus on analytics and subscription models, with new platform launches planned through 2026.
Life sciences expected to have the highest long-term growth potential, followed by IP and A&G.
Product innovation and AI initiatives
Significant investments in product development, content expansion, and AI integration across all segments.
Web of Science enhancements include a new UI, expanded journal coverage, and AI-powered Researcher Assistant.
AI-driven products like TrademarkVision and MotionHall are already contributing to growth and customer value.
AI and GenAI investments are a meaningful and growing part of the budget, with benefits expected to materialize in 2025 and beyond.
Integration of content and tools across platforms (e.g., ProQuest, Alma, InCites) is a key focus for future product improvements.
Revenue mix, pricing, and margin outlook
Emphasis on growing recurring and subscription revenue streams, with ongoing portfolio review to divest non-core or growth-dilutive businesses.
Pricing increases have historically been 3-4%, with future upside tied to enhanced product value and innovation.
Margins are expected to compress in the near term due to reinvestment, but margin expansion is targeted as organic growth accelerates.
Productivity gains from AI tools are improving development efficiency, with potential for future cost savings.
EBITDA margin expansion of 50+ basis points annually is seen as reasonable once mid-single-digit growth is achieved.
Latest events from Clarivate
- Accelerating recurring revenue and AI-driven innovation while divesting Life Sciences to boost growth.CLVT
Wolfe FinTech Forum10 Mar 2026 - Exceeded guidance, improved recurring revenue, and set 2026 growth targets amid portfolio shift.CLVT
Q4 202524 Feb 2026 - Q2 revenue fell and net loss widened on impairment, but guidance and renewal rates held firm.CLVT
Q2 20242 Feb 2026 - Guidance lowered for organic growth, but AI innovation and buybacks signal a strategic shift.CLVT
Oppenheimer 27th Virtual Annual Technology, Internet & Communications Conference2 Feb 2026 - AI-driven innovation and recurring revenue focus set the stage for accelerated growth and margin gains.CLVT
Stifel 2024 Cross Sector Insight Conference1 Feb 2026 - Targeting 4%-6% organic growth by 2026 through innovation, AI, and recurring revenue.CLVT
The 44th Annual William Blair Growth Stock Conference31 Jan 2026 - Q3 revenue dropped 3.9% as losses widened and a strategic shift toward recurring revenue began.CLVT
Q3 202416 Jan 2026 - Q1 2025 saw organic growth, margin expansion, and stable free cash flow amid divestitures.CLVT
Q1 202524 Dec 2025 - Shift to subscriptions and disposals aims to boost margins, predictability, and organic growth.CLVT
Q4 202416 Dec 2025